Jagsonpal Pharmaceuticals Limited — Investor Meet, 31-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma delivered strong Q1FY26 results: Revenue climbed 23% YoY to Rs. 75.5 Cr, with PAT doubling to Rs. 10.8 Cr and EBITDA margins at 20.8%. Gross margins expanded to 64.4%. The company maintains a robust Rs. 161 Cr cash balance. Management reiterated its 15% FY26 growth outlook (9-10% organic), driven by improved MR productivity and reduced attrition. Strategic focus includes India-centric brand or business acquisitions in subchronic therapies, with flexibility in deal size. The management conveys a confident outlook on its growth trajectory and financial discipline.